The bill amends several sections of the Code of West Virginia concerning controlled substance schedules, specifically targeting updates to classifications of various drugs, including opiates, hallucinogens, and synthetic cannabinoids. It clarifies that fentanyl and carfentanil will remain classified as Schedule II substances, while various fentanyl analogs and derivatives will be included in Schedule I. The legislation introduces extensive lists of new synthetic substances, including tryptamines, depressants, and stimulants, ensuring that any immediate precursors or derivatives are also covered under the new regulations. Additionally, it establishes a temporary listing for certain substances subject to emergency scheduling to address the rise of new psychoactive substances.

The bill further updates classifications under Schedule IV and Schedule V, adding new substances such as Daridorexant, Lemborexant, and Zuranolone to Schedule IV, while excluding human chorionic gonadotropin from this classification when used in nonhuman species with FDA approval. It also introduces new depressants and stimulants to Schedule V, including Ezogabine, Ganaxolone, and Lacosamide, and outlines specific limits for various narcotic drugs and their combinations with nonnarcotic active medicinal ingredients. These changes aim to enhance the regulation and monitoring of controlled substances in West Virginia, reflecting current medical practices and public health concerns, with the bill set to take effect 90 days after passage.

Statutes affected:
Introduced Version: 60A-2-204, 60A-2-206, 60A-2-208, 60A-2-210, 60A-2-212
Engrossed Version: 60A-2-204, 60A-2-206, 60A-2-208, 60A-2-210, 60A-2-212
Enrolled Version: 60A-2-204, 60A-2-206, 60A-2-208, 60A-2-210, 60A-2-212